FIELD: medicine.
SUBSTANCE: treating schizophrenia is preceded by carrying out the immunological examination and measuring the biochemical values of blood serum. A high efficacy of neuroleptic therapy can be expected if observing a combination of natural killers (CD16+) 0.22·109/L and more, lymphocytes with lazy activation markers (HLADR+) 0.56·109/L and serum aspartate aminotransferase (AST) 20.76 U/L and less.
EFFECT: using the given method enables predicting the clinical effectiveness prior to the active psychopharmacological treatment with traditional neuroleptics and taking the target rehabilitation psychopharmacological actions.
2 ex, 1 tbl
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR PREDICTING EFFECTIVENESS OF OLANZAPINE ATYPICAL ANTIPSYCHOTIC DRUG THERAPY IN SCHIZOPHRENIA PATIENTS | 2017 |
|
RU2680529C1 |
METHOD FOR PREDICTING THE EFFECTIVENESS OF TREATMENT OF PATIENTS WITH SCHIZOPHRENIA | 2021 |
|
RU2775440C1 |
METHOD OF TREATING PATIENTS WITH SCHIZOPRENIA | 2009 |
|
RU2415666C1 |
METHOD FOR PREDICTING THE EFFICIENCY OF TREATING PATIENTS WITH SCHIZOPHRENIA WITH ATYPICAL NEUROLEPTIC QUETIAPIN (SEROQUEL) | 2005 |
|
RU2289137C1 |
METHOD FOR TREATING THE CASES OF SCHIZOPHRENIA | 2000 |
|
RU2164799C1 |
METHOD FOR PREDICTING THE EFFICIENCY OF TREATING RESIDUAL SCHIZOPHRENIA WITH ATYPICAL NEUROLEPTICS | 2006 |
|
RU2319155C2 |
METHOD OF TREATING SCHIZOPHRENIA | 2011 |
|
RU2484836C2 |
METHOD FOR PREDICTING THERAPY EFFICIENCY FOR PATIENTS WITH ADJUSTMENT DISORDERS WITH ANXIETY-DEPRESSIVE SYMPTOMATIC | 2018 |
|
RU2677867C1 |
USE OF METHYL ETHER OF N-CAPROYL-L-PROLYL-L-TYROSINE (DILEPT) AS AGENT WITH PSYCHOSTIMULANT ACTIVITY | 2015 |
|
RU2593886C1 |
METHOD OF EFFICIENCY FORECAST FOR RESIDUAL SHIZOPHRENIA TREATMENT BY ATYPICAL NEUROLEPTIC QUETIAPINE | 2007 |
|
RU2349918C1 |
Authors
Dates
2015-04-10—Published
2014-04-08—Filed